Fianlimab (Biosimilar Reference Antibody) (LAG3)
Fianlimab (Biosimilar Reference Antibody) (LAG3)
Fianlimab (Biosimilar Reference Antibody) (LAG3)-RA0454-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
ELISA plate pre-coated Antigen protein, can bind Fianlimab (Biosimilar Reference Antibody) (LAG3)-RA0454 in a linear range of 3.91-125 ng/mL.
Fianlimab (Biosimilar Reference Antibody) (LAG3)

Catalog: 

RA0454

Target

LAG3/CD223

Isotype

IgG4 - kappa

Applications

ELISA;FC;Functional Assays;IF

Reactivities

Human

Size ($):

100 μg-50;1 mg-210;5 mg-500;10 mg-800;25 mg-1750;50 mg-3000;100 mg-4600

Data Sheet

Material Safety Data Sheet

Certificate of Analysis

Product Description

Fianlimab (development code REGN-3767) is an investigational, fully human monoclonal antibody being developed for cancer immunotherapy. It functions as an antagonist of the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. By binding with high affinity to LAG-3 on the surface of T cells and other immune cells, fianlimab blocks its interaction with major histocompatibility complex class II (MHC-II) molecules and other ligands. This blockade releases the inhibitory signal that LAG-3 imposes on T-cell activation, proliferation, and effector function, thereby aiming to restore anti-tumor immune responses, particularly in T cells that are exhausted or dysfunctional. Its development often focuses on combination therapy with other checkpoint inhibitors.

Synonyms

REGN3767

CAS

2126132-98-5

Isotype

IgG4 - kappa

Host

Genetically human

Target

LAG3/CD223

Reactivity

Human

Expression System

CHO

Applications

ELISA, FC, Functional Assays, IF; Recommended dilution: FC, IF:1:200

Purity

>98% by SDS-PAGE

Concentration

Bottled at the concentration indicated on the vial.

Buffer

0.01M PBS, pH 7.4, contains no stabilizers or preservatives.

Endotoxin

<1.0 EU/mg as determined by LAL method

Conjugation

Non-conjugated

Formulation

Liquid or Lyophilized powder Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

store at -20°C or -80°C. Avoid repeated freeze.

Type

Antibody

Purposes

For research use only

References 1

Omid Hamid, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.Meeting Abstract | 2021 ASCO Annual Meeting I.

References 2

Burova E, et al., Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062.

References 3

References 4

References 5

Product Citations 1

Product Citations 2

https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9515
https://pubmed.ncbi.nlm.nih.gov/31395688/
https://www.oursmab.com/News/The-immune-checkpoint-LAG-3.html

Target Description

Synonyms

lymphocyte activating 3, lymphocyte-activation 3, CD223

Biology Area

Immune Checkpoint;Immunology;CD Markers

Function

Lymphocyte Activation Gene-3 (LAG-3), also known as CD223. LAG-3 is a type I transmembrane protein and a member of the immunoglobulin superfamily, structurally related to CD4. It is expressed on activated and exhausted CD4+ and CD8+ T cells, regulatory T cells (Tregs), and some NK cells. LAG-3 acts as a co-inhibitory immune checkpoint receptor. Its binding to MHC-II molecules on antigen-presenting cells (APCs) or tumor cells delivers a potent negative signal that suppresses T-cell receptor (TCR) signaling, cytokine production, and T-cell proliferation. LAG-3 is frequently co-expressed with PD-1 on exhausted T cells within the tumor microenvironment, contributing to tumor immune escape.

Additional Articles 1

The-immune-checkpoint-LAG-3

Additional Articles 2

Related Products

Catalog: 

RA0454

Target:

CD274/PDL1/B7H1

Isotype:

IgG - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Catalog: 

RA0454

Target:

IL6R/CD126

Isotype:

IgG1 - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Catalog: 

RA0454

Target:

Zaire Ebolaviru...

Isotype:

IgG1 - kappa

Applications:

Functional Assays

Reactivities:

Virus

Catalog: 

RA0454

Target:

IL7R/CD127

Isotype:

IgG1 - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Catalog: 

RA0454

Target:

Zaire Ebolaviru...

Isotype:

IgG1 - kappa

Applications:

Functional Assays

Reactivities:

Virus

Catalog: 

RA0454

Target:

IL7R/CD127

Isotype:

IgG4 - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Catalog: 

RA0454

Target:

Zaire Ebolaviru...

Isotype:

IgG1 - kappa

Applications:

Functional Assays

Reactivities:

Virus

Catalog: 

RA0454

Target:

Zaire Ebolaviru...

Isotype:

IgG1 - kappa

Applications:

Functional Assays

Reactivities:

Virus

Catalog: 

RA0454

Target:

IL9

Isotype:

IgG1 - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Catalog: 

RA0454

Target:

ILDR2

Isotype:

IgG2 - kappa

Applications:

ELISA;FC;Functional Assays;IF

Reactivities:

Human

Contact Us

Send your request

Talk to us 

Get a quotation, discuss your requirement, receive advises from our antibody experts without obligation.